Natriuretic Peptide, Brain

• 

  Subject Areas on Research

  • A Canadian context for the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) trial. 
  • A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). 
  • A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. 
  • A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. 
  • A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. 
  • Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. 
  • Acute decompensated heart failure: update on new and emerging evidence and directions for future research. 
  • Acute heart failure: perspectives from a randomized trial and a simultaneous registry. 
  • Adding Troponin to the Puzzle of Heart Failure With Preserved Ejection Fraction: Marker or Mediator? 
  • Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. 
  • Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. 
  • Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. 
  • Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction. 
  • Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. 
  • Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure. 
  • Apolipoprotein E Polymorphism, Cardiac Remodeling, and Heart Failure in the ARIC Study. 
  • Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure? 
  • Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). 
  • Assessing prognosis in heart failure: is hepatocyte growth factor the next B-type natriuretic peptide? 
  • Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. 
  • Assessing the incremental predictive performance of novel biomarkers over standard predictors. 
  • Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy. 
  • Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. 
  • Assessment of functional capacity before major non-cardiac surgery: an international, prospective cohort study. 
  • Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment: the Japan Morning Surge-Target Organ Protection (J-TOP) study. 
  • Association between natriuretic peptides and mortality among patients admitted with myocardial infarction: a report from the ACTION Registry(R)-GWTG™. 
  • Association of Left Atrial Structure and Function With Heart Failure in Older Adults. 
  • Association of cardiac biomarkers with acute kidney injury after cardiac surgery: A multicenter cohort study. 
  • Association of circulating cardiac biomarkers with electrocardiographic abnormalities in chronic kidney disease. 
  • Association of high-sensitivity cardiac troponin T and N-terminal pro-brain-type natriuretic peptide with left ventricular structure: J-HOP study. 
  • Association of home and ambulatory blood pressure changes with changes in cardiovascular biomarkers during antihypertensive treatment. 
  • Association of morning and evening blood pressure at home with asymptomatic organ damage in the J-HOP Study. 
  • Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. 
  • Association of serum triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction. 
  • Associations of osteopontin and NT-proBNP with circulating miRNA levels in acute coronary syndrome. 
  • Atrial and brain natriuretic peptide concentrations and the response to inhaled nitric oxide in patients with acute respiratory distress syndrome. 
  • Atrial natriuretic polypeptide as a novel antigrowth factor of endothelial cells. 
  • B-type natriuretic peptide - a biomarker for all seasons? 
  • B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. 
  • B-type natriuretic peptide assessment in ambulatory heart failure patients: insights from IMPROVE HF. 
  • B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: insights from the Acute Decompensated Heart Failure National Registry. 
  • B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. 
  • BNP-guided heart failure therapy in older patients. 
  • BNP-guided therapy for heart failure. 
  • Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials. 
  • Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. 
  • Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. 
  • Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. 
  • Bedside prediction of increased filling pressure using acoustic electrocardiography. 
  • Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. 
  • Biomarker bonanza? 
  • Biomarker guided therapy for heart failure: focus on natriuretic peptides. 
  • Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes. 
  • Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. 
  • Biomarker-based risk prediction in the community. 
  • Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. 
  • Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. 
  • Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. 
  • Biomarkers in atrial fibrillation: a clinical review. 
  • Biomarkers in cardiovascular clinical trials: past, present, future. 
  • Biomarkers of Congestion: Emerging Tools in the Management of Heart Failure? 
  • Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. 
  • Body Composition, Natriuretic Peptides, and Adverse Outcomes in Heart Failure With Preserved and Reduced Ejection Fraction. 
  • Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. 
  • Brain Natriuretic Peptide Treatment and Heart Failure Prevention: Reliving the Mistakes of the Past or Charting a New Course for the Future? 
  • Brain natriuretic peptide improves long-term functional recovery after acute CNS injury in mice. 
  • Brain natriuretic peptide: diagnostic and therapeutic implications in pulmonary arterial hypertension. 
  • Can we prevent heart failure with exercise? 
  • Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. 
  • Cardiac phenotype and angiotensin II levels in AT1a, AT1b, and AT2 receptor single, double, and triple knockouts. 
  • Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. 
  • Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. 
  • Changes in B-type natriuretic peptide improve weaning outcome predicted by spontaneous breathing trial. 
  • Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change. 
  • Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score. 
  • Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study. 
  • Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. 
  • Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. 
  • Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). 
  • Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. 
  • Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score. 
  • Clinical predictors and hemodynamic consequences of elevated peripheral chemosensitivity in optimally treated men with chronic systolic heart failure. 
  • Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial. 
  • Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. 
  • Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF Study. 
  • Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. 
  • Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. 
  • Comparison of Dyspnea Measurement Instruments in Acute Heart Failure: The DYSPNEA-AHF Pilot Study. 
  • Comparison of clinical characteristics, treatments and outcomes of patients with ST-elevation acute myocardial infarction with versus without new or presumed new left bundle branch block (from NCDR®). 
  • Comparison of hand-carried ultrasound assessment of the inferior vena cava and N-terminal pro-brain natriuretic peptide for predicting readmission after hospitalization for acute decompensated heart failure. 
  • Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Coping styles in heart failure patients with depressive symptoms. 
  • Coronary Slow Flow Phenomenon - Adding Myocardial Fibrosis to the Equation. 
  • Correlation between peak expiratory flow rate and NT-proBNP in patients with acute heart failure. An analysis from ASCEND-HF trial. 
  • Correlation of serum brain natriuretic peptide with hyponatremia and delayed ischemic neurological deficits after subarachnoid hemorrhage. 
  • Counting Steps: A New Way to Monitor Patients with Pulmonary Arterial Hypertension. 
  • Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. 
  • Current Controversies in Caring for the Critically Ill Pulmonary Embolism Patient. 
  • Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. 
  • Defining and refining heart failure risk stratification to optimize patient selection for cardiac transplantation. 
  • Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. 
  • Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). 
  • Diagnostic characteristics of combining phonocardiographic third heart sound and systolic time intervals for the prediction of left ventricular dysfunction. 
  • Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. 
  • Differences in treatment, outcomes, and quality of life among patients with heart failure in Canada and the United States. 
  • Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). 
  • Discriminative capacity of biomarkers for acute stroke in the emergency department. 
  • Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction. 
  • Dual natriuretic peptide system in experimental heart failure. 
  • Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. 
  • Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. 
  • Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. 
  • Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 
  • Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. 
  • Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 
  • Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. 
  • Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. 
  • Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. 
  • Effect of nesiritide in patients with acute decompensated heart failure. 
  • Effect of obesity on B-type natriuretic peptide levels in patients with pulmonary arterial hypertension. 
  • Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. 
  • Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). 
  • Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. 
  • Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. 
  • Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. 
  • Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. 
  • Efficacy and safety of nesiritide in patients with acute decompensated heart failure. 
  • Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial. 
  • Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA. 
  • Emergency thoracic ultrasound in the differentiation of the etiology of shortness of breath (ETUDES): sonographic B-lines and N-terminal pro-brain-type natriuretic peptide in diagnosing congestive heart failure. 
  • Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. 
  • Evaluation of a provocative dyspnea severity score in acute heart failure. 
  • Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure. 
  • Exacerbation of anthracycline-induced early chronic cardiomyopathy with ATRA: role of B-type natriuretic peptide as an indicator of cardiac dysfunction. 
  • Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance Aggregometry for the Assessment of Platelet Function in Patients with Congestive Heart Failure. 
  • Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. 
  • Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. 
  • Fontan-associated protein-losing enteropathy and heart transplant: A Pediatric Heart Transplant Study analysis. 
  • Galectin 3 complements BNP in risk stratification in acute heart failure. 
  • Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. 
  • Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. 
  • Genetic Dissection of Cardiac Remodeling in an Isoproterenol-Induced Heart Failure Mouse Model. 
  • Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). 
  • Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. 
  • Guideline-based decision support has a small, non-sustained effect on transthoracic echocardiography ordering frequency. 
  • Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. 
  • High-sensitivity C-reactive protein and parameters of left ventricular dysfunction. 
  • High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. 
  • High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study. 
  • Highest Obesity Category Associated With Largest Decrease in N-Terminal Pro-B-Type Natriuretic Peptide in Patients Hospitalized With Heart Failure With Preserved Ejection Fraction. 
  • History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. 
  • Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. 
  • How does intermittent pacing modify the response to rapid ventricular pacing in experimental heart failure? 
  • How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. 
  • Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. 
  • Impact of Diabetes and Hypertension on Left Ventricular Structure and Function: The Jackson Heart Study. 
  • Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. 
  • In Reply: B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: Insights from the ADHERE registry. 
  • Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. 
  • Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. 
  • Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. 
  • Incremental prognostic value of biomarkers beyond the GRACE (Global Registry of Acute Coronary Events) score and high-sensitivity cardiac troponin T in non-ST-elevation acute coronary syndrome. 
  • Independent prognostic value of echocardiography and N-terminal pro-B-type natriuretic peptide in patients with heart failure. 
  • Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). 
  • Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. 
  • Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. 
  • Influence of imprecision on ROC curve analysis for cardiac markers. 
  • Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. 
  • Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline? 
  • Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial. 
  • Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). 
  • Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. 
  • Intravenous fluid resuscitation is associated with septic endothelial glycocalyx degradation. 
  • Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. 
  • Laboratory measures of exercise capacity and ventricular characteristics and function are weakly associated with functional health status after Fontan procedure. 
  • Left Atrial Structure and Function in Heart Failure with Preserved Ejection Fraction: A RELAX Substudy. 
  • Left ventricular dysfunction screening in hypertensive patients with N-terminal pro-B-type natriuretic peptide and electrocardiogram. 
  • Level and Change in N-Terminal Pro-B-Type Natriuretic Peptide and Kidney Function and Survival to Age 90. 
  • Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. 
  • Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. 
  • Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. 
  • Measurement of Exercise Tolerance before Surgery (METS) study: a protocol for an international multicentre prospective cohort study of cardiopulmonary exercise testing prior to major non-cardiac surgery. 
  • Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). 
  • Medical resource use, costs, and quality of life in patients with acute decompensated heart failure: findings from ASCEND-HF. 
  • Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. 
  • Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. 
  • Midregional Pro-Atrial Natriuretic Peptide and Atrial Fibrillation: Interesting Association or Practice Changing? 
  • Mode of death and hospitalization from the Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial and comparison of clinical events committee adjudicated versus investigator reported outcomes. 
  • Multi-marker strategies in heart failure: clinical and statistical approaches. 
  • Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. 
  • Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up. 
  • Multiple biomarkers at admission are associated with angiographic, electrocardiographic, and imaging cardiovascular mechanistic markers of outcomes in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. 
  • Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) - Phase I Evaluation of the Integration and Safety of the HeartLogic Multisensor Algorithm in Patients With Heart Failure. 
  • N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. 
  • N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements. 
  • N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. 
  • N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). 
  • N-terminal pro-B-type natriuretic peptide: a risk predictor for all. 
  • N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. 
  • N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. 
  • N-terminal pro-brain natriuretic peptide and outcomes in patients undergoing surgical ventricular restoration. 
  • N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. 
  • NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. 
  • National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. 
  • National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. 
  • National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biomarkers of heart failure. 
  • National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. 
  • Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. 
  • Natriuretic Peptides and Stratification for ICD Therapy in Nonischemic Heart Failure: A Definite Maybe? 
  • Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper. 
  • Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. 
  • Natriuretic peptide-guided heart failure management. 
  • Natriuretic peptide-guided management in heart failure. 
  • Natriuretic peptides and long-term mortality in patients with severe aortic stenosis. 
  • Natriuretic peptides and primary prevention: the new world? 
  • Natriuretic peptides in the diagnosis and management of heart failure. 
  • Nesiritide in acute decompensated heart failure. 
  • Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. 
  • Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF). 
  • Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. 
  • Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction. 
  • Novel Biomarkers, ST-Elevation Resolution, and Clinical Outcomes Following Primary Percutaneous Coronary Intervention. 
  • Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. 
  • Obese patients have lower B-type and atrial natriuretic peptide levels compared with nonobese. 
  • Overview of current noninodilator therapies for acute heart failure syndromes. 
  • PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. 
  • Patterns and implications of B-type natriuretic peptide measurement in patients with non-ST-segment elevation acute coronary syndromes. 
  • Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. 
  • Performance of phonoelectrocardiographic left ventricular systolic time intervals and B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction. 
  • Perioperative nesiritide and possible renal protection in patients with moderate to severe kidney dysfunction. 
  • Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). 
  • Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial. 
  • Plasma and cardiac tissue atrial and brain natriuretic peptides in experimental heart failure. 
  • Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. 
  • Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. 
  • Point-of-Care Ultrasound Abnormalities in Late-Onset Severe Preeclampsia: Prevalence and Association With Serum Albumin and Brain Natriuretic Peptide. 
  • Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis. 
  • Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. 
  • Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone [corrected] concentrations in ST elevation myocardial infarction: an analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial. 
  • Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) Study. 
  • Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. 
  • Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. 
  • Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. 
  • Predictors of proarrhythmic effect in heart failure patients after 9-week hybrid comprehensive telerehabilitation and their influence on cardiovascular mortality in long-term follow-up: Subanalysis of the TELEREH-HF randomized clinical trial. 
  • Preliminary report on cardiac dysfunction after isolated traumatic brain injury. 
  • Preoperative serum brain natriuretic peptide and risk of acute kidney injury after cardiac surgery. 
  • Prevalence, Profile, and Prognosis of Severe Obesity in Contemporary Hospitalized Heart Failure Trial Populations. 
  • Preventing heart failure. 
  • Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction. 
  • Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. 
  • Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial. 
  • Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. 
  • Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. 
  • Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. 
  • Prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure trials. 
  • Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement. 
  • Prognostic value of serial B-type natriuretic peptide measurement in transcatheter aortic valve replacement (from the PARTNER Trial). 
  • Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. 
  • Prospective Observational Study of N-terminal Pro-Brain Natriuretic Peptide Levels in Obese and Nonobese Women during Pregnancy. 
  • Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 (PROACT-3). 
  • Racial Differences in Serial NT-proBNP Levels in Heart Failure Management: Insights From the GUIDE-IT Trial. 
  • Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. 
  • Racial/Ethnic differences in B-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure. 
  • Radiographic and Clinical Predictors of Cardiac Dysfunction Following Isolated Traumatic Brain Injury. 
  • Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). 
  • Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. 
  • Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. 
  • Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). 
  • Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. 
  • Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. 
  • Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF). 
  • Reactive hyperemia is associated with adverse clinical outcomes in heart failure. 
  • Red blood cell distribution width and 1-year mortality in acute heart failure. 
  • Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19. 
  • Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. 
  • Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). 
  • Relation of anemia to diastolic heart failure and the effect on outcome. 
  • Relation of level of B-type natriuretic peptide with outcomes in patients with infective endocarditis. 
  • Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. 
  • Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. 
  • Relationship between B-type natriuretic peptide and adverse outcome in patients with clinical evidence of sepsis presenting to the emergency department. 
  • Relationship between accurate auscultation of a clinically useful third heart sound and level of experience. 
  • Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry. 
  • Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. 
  • Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. 
  • Reply: Higher N-terminal Pro-B-type natriuretic peptide may be related to very different conditions. 
  • Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF. 
  • Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. 
  • Results of the FUEL Trial. 
  • Risk factors for cardiovascular disease across the spectrum of older age: the Cardiovascular Health Study. 
  • Role of guanylate cyclase modulators in decompensated heart failure. 
  • S100B and brain natriuretic peptide predict functional neurological outcome after intracerebral haemorrhage. 
  • Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. 
  • Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. 
  • Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. 
  • Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat. 
  • Serial measurements of N-terminal pro-brain natriuretic peptide in patients with coronary heart disease. 
  • Serum Pro-N-Cadherin Is a Marker of Subclinical Heart Failure in the General Population. 
  • Serum brain natriuretic peptide and risk of acute kidney injury after cardiac operations in children. 
  • Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers. 
  • Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). 
  • Stress-Delta B-Type Natriuretic Peptide Does Not Exclude ACS in the ED. 
  • Stretching for prediction: the case for brain natriuretic peptide. 
  • Subcutaneous B-type natriuretic peptide for treatment of heart failure: a dying therapy reborn? 
  • Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure). 
  • Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. 
  • Surfing the biomarker tsunami at JACC: heart failure. 
  • Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. 
  • Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. 
  • Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome. 
  • Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction. 
  • Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. 
  • The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. 
  • The ABCs of managing systolic heart failure: Past, present, and future. 
  • The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. 
  • The Degree of the Predischarge Pulmonary Congestion in Patients Hospitalized for Worsening Heart Failure Predicts Readmission and Mortality. 
  • The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). 
  • The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. 
  • The change in B-type natriuretic peptide levels over time predicts significant rejection in cardiac transplant recipients. 
  • The combined utility of an S3 heart sound and B-type natriuretic peptide levels in emergency department patients with dyspnea. 
  • The disconnect between phase II and phase III trials of drugs for heart failure. 
  • The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. 
  • The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. 
  • The long-term effects of dietary sodium restriction on clinical outcomes in patients with heart failure. The SODIUM-HF (Study of Dietary Intervention Under 100 mmol in Heart Failure): a pilot study. 
  • The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial. 
  • Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? 
  • Time for a Renewed Focus on the DASH-Low Sodium Diet. 
  • Time, now, to recover the fun in the physical examination rather than abandon it. 
  • Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). 
  • Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. 
  • Treatment-related biomarkers in pulmonary hypertension. 
  • Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). 
  • Troponin I and NT-proBNP and the association of systolic blood pressure with outcomes in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. 
  • Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. 
  • Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. 
  • Unraveling the pathophysiology of acute heart failure: an inflammatory proposal. 
  • Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. 
  • Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial. 
  • Use of hand carried ultrasound, B-type natriuretic peptide, and clinical assessment in identifying abnormal left ventricular filling pressures in patients referred for right heart catheterization. 
  • Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy). 
  • Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes. 
  • Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. 
  • Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. 
  • Utilization of hospice and predicted mortality risk among older patients hospitalized with heart failure: findings from GWTG-HF. 
  • Vasodilators in the treatment of acute heart failure: what we know, what we don't. 
  • What to expect from net reclassification improvement with three categories. 
  • Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. 
  • Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). 
• 

  Keywords of People

  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • James, Michael Lucas, Associate Professor of Anesthesiology, Anesthesiology
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Science & Society
  • Limkakeng Jr., Alexander Tan, Professor of Emergency Medicine, Emergency Medicine
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Patel, Uptal Dinesh, Adjunct Professor in the Department of Medicine, Medicine, Nephrology